Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder

Acta Psychiatrica Scandinavica

Volumn 115, Issue 5, 2007, Pages 388-394

  Hasselbalch, S G ^a   Hansen, E S ^a   Jakobsen, T B ^a   Pinborg, L H ^a   Lonborg J H ^b   Bolwig, T G ^a  

^a Rigshospitalet   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Obsessive compulsive disorder; Serotonin; Single photon emission computerized tomography

Indexed keywords

IODINE 123; SEROTONIN TRANSPORTER;

ADULT; AGE DISTRIBUTION; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; MALE; MESENCEPHALON; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PONS; PRIORITY JOURNAL; PROTEIN BINDING; RATING SCALE; SCORING SYSTEM; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SEX RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; COCAINE; FEMALE; FRONTAL LOBE; HUMANS; IODINE RADIOISOTOPES; MALE; MESENCEPHALON; MIDDLE AGED; NERVE NET; OBSESSIVE-COMPULSIVE DISORDER; PONS; REFERENCE VALUES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STATISTICS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34147160701     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2006.00940.x     Document Type: Article

References (28)

1. WEISSMAN MM, BLAND RC, CANINO GJ et al. The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. J Clin Psychiatry 1994;55(Suppl.):5-10.
2. MCGUIRE PK, BENCH CJ, FRITH CD et al. Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry 1994;164:459-468.
3. BREITER HC, RAUCH SL, KWONG KK et al. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry 1996;53:595-606.
4. BAXTER LR Jr, SCHWARTZ JM, MAZZIOTTA JC et al. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 1988;145:1560-1563.
5. PERANI D, COLOMBO C, BRESSI S et al. [18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry 1995;166:244-250.
6. SAXENA S, BRODY AL, MAIDMENT KM et al. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 1999;21:683-693.
7. HANSEN ES, HASSELBALCH S, LAW I, BOLWIG TG. The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. Int J Neuropsychopharmacol 2002;5:1-10.
8. SAXENA S, BRODY AL, HO ML et al. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry 2002;59:250-261.
9. ADAMS KH, HANSEN ES, PINBORG LH et al. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol 2005;8:391-401.
10. MARAZZITI D, ROSSI A, GEMIGNANI A et al. Decreased platelet 3H-paroxetine binding in obsessive-compulsive patients. Neuropsychobiology 1996;34:184-187.
11. SALLEE FR, RICHMAN H, BEACH K, SETHURAMAN G, NESBITT L. Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1996;35:1647-1656.
12. SIMPSON HB, LOMBARDO I, SLIFSTEIN M et al. Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with. Biol Psychiatry 2003;54:1414-1421.
13. VAN DER WEE NJ, STEVENS H, HARDEMAN JA et al. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by. Am J Psychiatry 2004;161:2201-2206.
14. POGARELL O, HAMANN C, POPPERL G et al. Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry 2003;54:1406-1413.
15. STENGLER-WENZKE K, MULLER U, ANGERMEYER MC, SABRI O, HESSE S. Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD). Eur Arch Psychiatry Clin Neurosci 2004;254:252-255.
16. LOGAN J, FOWLER JS, VOLKOW ND, WANG GJ, DING YS, ALEXOFF DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
17. EISEN JL, PHILLIPS KA, BAER L et al. The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry 1998;155:102-108.
18. HAMILTON M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
19. GOODMAN WK, PRICE LH, RASMUSSEN SA et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011.
20. PINBORG LH, ZIEBELL M, FROKJAER VG et al. Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. J Nucl Med 2005;46:1119-1127.
21. MINTUN MA, RAICHLE ME, KILBOURN MR, WOOTEN GF, WELCH MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15:217-227.
22. LARUELLE M, BALDWIN RM, MALISON RT et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
23. LARUELLE M, WALLACE E, SEIBYL JP et al. Graphical, kinetic, and equilibrium analyses of in vivo 123I beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
24. PIRKER W, ASENBAUM S, HAUK M et al. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000;41:36-44.
25. SIMPSON HB, LOMBARDO I, SLIFSTEIN M et al. Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652. Biol Psychiatry 2003;54:1414-1421.
26. STALEY JK, KRISHNAN-SARIN S, ZOGHBI S et al. Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 2001;41:275-284.
27. VAN DYCK CH, MALISON RT, SEIBYL JP et al. Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. Neurobiol Aging 2000;21:497-501.
28. MÜLLER-VAHL KR, MEYER GJ, KNAPP WH et al. Serotonin transporter binding in Tourette syndrome. Neurosci Lett 2005;385:120-125.